Montelukast API Market By Product Type (Montelukast Sodium Amorphous, Montelukast Sodium Crystalline) By Dosage Form ( Tablet, Chewable Tablet, Oral Solution) By Application (Asthma, Allergic Rhinitis, Urticaria, Bronchospasm, Others) – Growth, Future Prospects & Competitive Analysis, 2016 – 2028

Market Insights

The global Montelukast API Market report explores the critical analysis of the montelukast API industry using key parameters. The report consists of investment strategies, the need for investments in the montelukast API industry, and the multiple benefits for the investors. Importantly, this report sets out major changes in the global technical regulations for the montelukast API industry and how economic and non-economic barriers are helping the market grow. Moreover, the report examines historic and forecasted market sizes at the global, regional, and country levels. The report also includes an in-depth examination of key investment propositions, the demand and supply gap, competitor positioning, SRC analysis, STAR analysis, and Tornado analysis. Important technological advancements and other analyses, including Porter’s Five Forces, PESTEL, Value Chain, etc.

Key Highlights of the report

How are the major segments performing in the Montelukast API Market?

The montelukast sodium amorphous segment led the market in terms of product type in 2021 and is expected to continue throughout the projection period. Montelukast sodium amorphous is an anti-allergic, anti-asthmatic, cytoprotective, and anti-inflammatory agent that can treat various diseases. In adults and children 12 months of age and older, montelukast sodium amorphous treats asthma symptoms like difficulty breathing, wheezing, chest tightness, and coughing. The use of montelukast sodium amorphous product type is growing along with the prevalence of asthma.

In 2021, the tablet segment in dosage form led the market due to factors such as lower manufacturing costs compared to other forms, preferred by the majority of people due to several advantages over powder and liquid forms such as no unpleasant odor as the drug is extremely compact and coated with enteric or sugar.

The asthma segment led the application market in 2021 and is expected to continue throughout the projection period. Asthma, one of the most common diseases in the world, affects patients’ ability to breathe normally and is a potentially fatal condition. Montelukast Sodium, also known as Singulair, is a leukotriene inhibitor used to treat complications associated with Asthma, such as shortness of breath. Montelukast sodium use rises in tandem with the global prevalence of asthma. According to the Centers for Disease Control and Prevention (CDC), asthma affects 1 in 13 people as of March 2021. All of the factors mentioned above and the benefits of using Montelukast sodium in treating asthma, urticaria, and the rising incidence of asthma contribute to the segment’s growth.

Which region dominated the Montelukast API Market?

North America dominated the global montelukast API market in 2021 due to leading manufacturers, the high prevalence of asthma and other respiratory diseases, and the region’s well-established health care infrastructural facilities. Government initiatives and expanded research collaborations are also anticipated to fuel the region’s market during the forecast period. The U.S. held the largest market share in North America in 2021, owing to favorable healthcare regulations, advanced healthcare facilities, and a large patient population. The Centers for Disease Control and Prevention estimate that 8.1% of Americans have asthma. As a result, increasing the country’s patient population and disposable income boosts the region’s market growth.

What is the competitive environment of the Montelukast API Market?

The key strategies adopted by the key players in the montelukast API market are acquisitions and mergers, product launches, joint ventures, and R&D. For instance, Morepen Laboratories received approval from the US Food and Drug Administration in December 2021 to market its generic anti-allergy drug (Fexofenadine Hydrochloride) in the US market. On the other hand, Valeo Pharma Inc. signed a commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. in March 2021 to commercialize their two asthma therapies in Canada.

Executive Summary

What are all technical developments being developed in the Montelukast API Market?

The global market for montelukast API has benefited greatly from the development of technologies. Increasing mergers and acquisitions among key market players, improving technological advancements, and huge investment in R&D activities by developed and developing regions worldwide are expected to drive market growth throughout the forecast period. For instance, Astellas Pharma Inc. and Iota Biosciences, Inc. announced a merger agreement in October 2020, after which Astellas will acquire Iota’s unique bioelectronics technology. Similarly, in July 2019, ADEA Medical AB, a Swedish provider of medical technologies and healthcare services, was purchased by BioTelemetry. This acquisition will add diagnostic products to the BioTelemetry portfolio.

Which are the key investments by the players in the Montelukast API Market?

Rising R&D investments in new drugs and technological advancements will open up lucrative opportunities for major market players. Various investments are made across the key player. For instance, since 2000, global R&D spending has more than tripled in real terms, rising from USD 677 billion to USD 2.2 trillion in 2019. On the other hand, Sandoz International acquired Aspen Global Incorporated in February 2019.

Some of the major players in the market are Cipla Ltd, Merck & Co. Inc, Morepen Laboratories, Sun Pharma, Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd, Apotex, Inc, Sanyo Chemical Industries Ltd, Mylan N.V., and Delmar Chemicals Inc.

What are the Major Driving Factors for the Montelukast API Market?

The rising prevalence of asthma is expected to drive market growth over the forecast period. The rise in respiratory diseases and the growing geriatric population are key factors driving the market growth. According to the World Health Organization, asthma affects approximately 235 million people worldwide. More than 80% of asthma-related deaths occur in low- and lower-middle-income countries. An increase in patients further drives demand for the montelukast API market over the forecast period.

What are the Major Risks for the Montelukast API Market?

While using montelukast sodium as a leukotriene inhibitor may help treat breathing problems, asthma, and many allergies, several health side effects could delay or prevent the market’s consistent growth. The rise in side effects such as nausea, stomach pain, diarrhea, and heartburn and lack of public awareness is expected to impede the market growth during the forecast period.

Which is the key Application in the Montelukast API Market

The asthma segment dominated the montelukast API market in 2021. One of the most widespread illnesses in the world, asthma is also a potentially fatal condition that impairs patients’ ability to breathe normally. It is a chronic condition that tightens and stretches the lungs’ airways, leading to recurrent episodes of shortness of breath, bronchospasm, and reversible airflow obstruction. Correspondingly, smoking has significantly increased, which makes asthma symptoms worse. Montelukast API treats asthma in adults and children 12 months of age by preventing symptoms like wheezing, breathing problems, chest tightness, and coughing. The use of montelukast API rises along with the global prevalence of asthma. 9.8 million visits to the doctor’s office, 188,968 discharges from hospital inpatient care, and 1.8 million trips to the emergency room are all attributed to asthma each year. As a result, the market is anticipated to grow rapidly due to the rising incidence and prevalence of asthma and the consequent increase in demand for montelukast API. The benefits of using montelukast API in treating urticaria, asthma, and the rising prevalence of asthma, among other factors, all contribute to the segment’s growth.

How is the Montelukast API Market performing in regions?

North America dominated the global montelukast API market in 2021 due to major players, the high prevalence of asthma and other respiratory diseases, and the developed healthcare infrastructure. Moreover, the Asthma and Allergy Foundation of America reported in April 2021 that about 25 million Americans worldwide have asthma. 8% of adults and 7% of children, or one in every thirteen Americans, fall into this category. Asthma affects approximately 20 million adults in the United States over 18. Asthma claims the lives of ten Americans every day. 3,524 people lost their lives to asthma in 2020.

Besides, Asia-Pacific is expected to grow the most during the forecast period due to an increasing geriatric population and asthma prevalence, as the elderly population is more susceptible to respiratory diseases. According to WHO reports, by 2050, one in every four people in the Asia Pacific region will be over 60, and the prevalence of asthma in the elderly population ranges from 1.3 to 15.3%, compared to 5% of adults in the region. Furthermore, rising asthma awareness and a growing regional healthcare sector are expected to drive market growth.

What is the regulatory landscape for the Montelukast API Market?

One of the factors anticipated to spur market growth is the increase in research partnerships and helpful government initiatives. Regulatory bodies may also specifically indicate some formulations, such as chewable montelukast tablets, for the prophylaxis and chronic care of asthma, including the prevention of daytime and night-time symptoms, the therapeutic interventions of acetylsalicylic acid-based asthma, and the prevention of exercise-induced bronchoconstriction in both adult and pediatric patients. Moreover, when used for these purposes, montelukast is thought to be effective either alone or in combination with other drugs for chronic asthma maintenance. Montelukast and inhaled corticosteroids, for instance, can be used concurrently to show additive effects to control asthma or to reduce the required dose of inhaled corticosteroids while still maintaining clinical stability.

What is the Market Size of the Montelukast API regarding value?

The global montelukast API market is anticipated to grow at a substantial CAGR of 9.8% in the upcoming years. The global montelukast API industry was estimated to be worth USD XX billion in 2021 and was expected to be worth USD XX billion by 2028.

What are the major players planning for the future of the Montelukast API Market?

There is a high demand for products and more effective delivery technologies to prevent asthma and other respiratory diseases. Besides, several government organizations and campaigns have increased funding for montelukast API production, expected to drive market growth during the forecast period. Asthma symptoms such as constricted airways in the lungs are prevented by the action of a substance blocked by montelukast sodium medication. It functions as both an antiasthmatic and a leukotriene receptor antagonist. To treat seasonal allergic rhinitis and prevent exercise-induced bronchoconstriction, market players will frequently use the leukotriene receptor antagonist montelukast as part of an asthma treatment plan.

Segmentation of Global Montelukast API Market –

Global Montelukast API Market – By Product Type

• Montelukast Sodium Amorphous
• Montelukast Sodium Crystalline

Global Montelukast API Market – By Dosage Form

• Tablet
• Chewable Tablet
• Oral Solution

Global Montelukast API Market – By Application

• Asthma
• Allergic Rhinitis
• Urticaria
• Bronchospasm
• Others

Global Montelukast API Market – By Region

• North America
  • The U.S.
  • Canada
• Europe
  • Germany
  • France
  • The U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global Montelukast API Market
2.2. Global Montelukast API Market, By Product Type
2.3. Global Montelukast API Market, By Dosage Form
2.4. Global Montelukast API Market, By Application
2.5. Global Montelukast API Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Montelukast API Market Value, 2016-2028, (US$ Bn)
3.2. Market Dynamics
3.2.1. Key Growth Trends
3.2.2. Market Drivers
3.2.3. Market Restraints
3.2.4. Market Opportunities
3.2.5. Major Industry Challenges
3.3. Attractive Investment Proposition,2021
3.3.1. Product Type
3.3.2. Dosage Form
3.3.3. Application
3.3.4. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Value Chain Analysis
4.4. Technology Analysis
4.5. Marketing Strategy Analysis
4.5.1. Direct Marketing
4.5.2. Indirect Marketing
4.5.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2021
5.1. Company market share of key players, 2021
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. COVID 19 Impact Analysis
6.1. Global Montelukast API Market Pre Vs Post COVID 19, 2019 – 2028
6.2. Impact on Import & Export
6.3. Impact on Demand & Supply

7. Global Montelukast API Market
7.1. Global Montelukast API Market, by Product Type, 2016-2028(US$ Bn)
7.1.1. Overview
7.1.2. Global Montelukast API Market, By Product Type, 2021 vs 2028 (in%)
7.1.3. Global Montelukast API Market, By Montelukast Sodium Amorphous, 2016-2028 (US$ Bn)
7.1.4. Global Montelukast API Market, By Montelukast Sodium Crystalline, 2016-2028 (US$ Bn)
7.2. Global Montelukast API Market, by Dosage Form, 2016-2028(US$ Bn)
7.2.1. Overview
7.2.2. Global Montelukast API Market, By Dosage Form, 2021 vs 2028 (in%)
7.2.3. Global Montelukast API Market, By Tablet, 2016-2028 (US$ Bn)
7.2.4. Global Montelukast API Market, By Chewable Tablet, 2016-2028 (US$ Bn)
7.2.5. Global Montelukast API Market, By Oral Solution, 2016-2028 (US$ Bn)
7.3. Global Montelukast API Market, by Application, 2016-2028(US$ Bn)
7.3.1. Overview
7.3.2. Global Montelukast API Market, By Application, 2021 vs 2028 (in%)
7.3.3. Global Montelukast API Market, By Asthma, 2016-2028 (US$ Bn)
7.3.4. Global Montelukast API Market, By Allergic Rhinitis, 2016-2028 (US$ Bn)
7.3.5. Global Montelukast API Market, By Urticaria, 2016-2028 (US$ Bn)
7.3.6. Global Montelukast API Market, By Bronchospasm, 2016-2028 (US$ Bn)
7.3.7. Global Montelukast API Market, By Others, 2016-2028 (US$ Bn)

8. North America Montelukast API Market Analysis
8.1. North America Montelukast API Market, by Product Type, 2016-2028(US$ Bn)
8.1.1. Overview
8.1.2. SRC Analysis
8.2. North America Montelukast API Market, by Dosage Form, 2016-2028(US$ Bn)
8.2.1. Overview
8.2.2. SRC Analysis
8.3. North America Montelukast API Market, by Application, 2016-2028(US$ Bn)
8.3.1. Overview
8.3.2. SRC Analysis
8.4. North America Montelukast API Market, by Country, 2016-2028 (US$ Bn)
8.4.1. U.S.
8.4.1.1. U.S. Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
8.4.1.2. U.S. Montelukast API, By Product Type, 2016-2028 (US$ Bn)
8.4.1.3. U.S. Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
8.4.1.4. U.S. Montelukast API, By Application, 2016-2028 (US$ Bn)
8.4.2. Canada
8.4.2.1. Canada Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
8.4.2.2. Canada Montelukast API, By Product Type, 2016-2028 (US$ Bn)
8.4.2.3. Canada Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
8.4.2.4. Canada Montelukast API, By Application, 2016-2028 (US$ Bn)

9. Europe Montelukast API Market Analysis
9.1. Europe Montelukast API Market, by Product Type, 2016-2028(US$ Bn)
9.1.1. Overview
9.1.2. SRC Analysis
9.2. Europe Montelukast API Market, by Dosage Form, 2016-2028(US$ Bn)
9.2.1. Overview
9.2.2. SRC Analysis
9.3. Europe Montelukast API Market, by Application, 2016-2028(US$ Bn)
9.3.1. Overview
9.3.2. SRC Analysis
9.4. Europe Montelukast API Market, by Country, 2016-2028 (US$ Bn)
9.4.1. Germany
9.4.1.1. Germany Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.4.1.2. Germany Montelukast API, By Product Type, 2016-2028 (US$ Bn)
9.4.1.3. Germany Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
9.4.1.4. Germany Montelukast API, By Application, 2016-2028 (US$ Bn)
9.4.2. France
9.4.2.1. France Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.4.2.2. France Montelukast API, By Product Type, 2016-2028 (US$ Bn)
9.4.2.3. France Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
9.4.2.4. France Montelukast API, By Application, 2016-2028 (US$ Bn)
9.4.3. UK
9.4.3.1. UK Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.4.3.2. UK Montelukast API, By Product Type, 2016-2028 (US$ Bn)
9.4.3.3. UK Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
9.4.3.4. UK Montelukast API, By Application, 2016-2028 (US$ Bn)
9.4.4. Italy
9.4.4.1. Italy Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.4.4.2. Italy Montelukast API, By Product Type, 2016-2028 (US$ Bn)
9.4.4.3. Italy Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
9.4.4.4. Italy Montelukast API, By Application, 2016-2028 (US$ Bn)
9.4.5. Spain
9.4.5.1. Spain Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.4.5.2. Spain Montelukast API, By Product Type, 2016-2028 (US$ Bn)
9.4.5.3. Spain Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
9.4.5.4. Spain Montelukast API, By Application, 2016-2028 (US$ Bn)
9.4.6. Rest of Europe
9.4.6.1. Rest of Europe Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.4.6.2. Rest of Europe Montelukast API, By Product Type, 2016-2028 (US$ Bn)
9.4.6.3. Rest of Europe Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
9.4.6.4. Rest of Europe Montelukast API, By Application, 2016-2028 (US$ Bn)

10. Asia Pacific Montelukast API Market Analysis
10.1. Asia Pacific Montelukast API Market, by Product Type, 2016-2028(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. Asia Pacific Montelukast API Market, by Dosage Form, 2016-2028(US$ Bn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. Asia Pacific Montelukast API Market, by Application, 2016-2028(US$ Bn)
10.3.1. Overview
10.3.2. SRC Analysis
10.4. Asia Pacific Montelukast API Market, by Country, 2016-2028 (US$ Bn)
10.4.1. China
10.4.1.1. China Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.4.1.2. China Montelukast API, By Product Type, 2016-2028 (US$ Bn)
10.4.1.3. China Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
10.4.1.4. China Montelukast API, By Application, 2016-2028 (US$ Bn)
10.4.2. Japan
10.4.2.1. Japan Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.4.2.2. Japan Montelukast API, By Product Type, 2016-2028 (US$ Bn)
10.4.2.3. Japan Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
10.4.2.4. Japan Montelukast API, By Application, 2016-2028 (US$ Bn)
10.4.3. India
10.4.3.1. India Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.4.3.2. India Montelukast API, By Product Type, 2016-2028 (US$ Bn)
10.4.3.3. India Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
10.4.3.4. India Montelukast API, By Application, 2016-2028 (US$ Bn)
10.4.4. South Korea
10.4.4.1. South Korea Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.4.4.2. South Korea Montelukast API, By Product Type, 2016-2028 (US$ Bn)
10.4.4.3. South Korea Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
10.4.4.4. South Korea Montelukast API, By Application, 2016-2028 (US$ Bn)
10.4.5. South-East Asia
10.4.5.1. South-East Asia Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.4.5.2. South-East Asia Montelukast API, By Product Type, 2016-2028 (US$ Bn)
10.4.5.3. South-East Asia Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
10.4.5.4. South-East Asia Montelukast API, By Application, 2016-2028 (US$ Bn)
10.4.6. Rest of Asia Pacific
10.4.6.1. Rest of Asia Pacific Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.4.6.2. Rest of Asia Pacific Montelukast API, By Product Type, 2016-2028 (US$ Bn)
10.4.6.3. Rest of Asia Pacific Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
10.4.6.4. Rest of Asia Pacific Montelukast API, By Application, 2016-2028 (US$ Bn)

11. Latin America Montelukast API Market Analysis
11.1. Latin America Montelukast API Market, by Product Type, 2016-2028(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Latin America Montelukast API Market, by Dosage Form, 2016-2028(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Latin America Montelukast API Market, by Application, 2016-2028(US$ Bn)
11.3.1. Overview
11.3.2. SRC Analysis
11.4. Latin America Montelukast API Market, by Country, 2016-2028 (US$ Bn)
11.4.1. Brazil
11.4.1.1. Brazil Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.4.1.2. Brazil Montelukast API, By Product Type, 2016-2028 (US$ Bn)
11.4.1.3. Brazil Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
11.4.1.4. Brazil Montelukast API, By Application, 2016-2028 (US$ Bn)
11.4.2. Mexico
11.4.2.1. Mexico Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.4.2.2. Mexico Montelukast API, By Product Type, 2016-2028 (US$ Bn)
11.4.2.3. Mexico Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
11.4.2.4. Mexico Montelukast API, By Application, 2016-2028 (US$ Bn)
11.4.3. Rest of Latin America
11.4.3.1. Rest of Latin America Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.4.3.2. Rest of Latin America Montelukast API, By Product Type, 2016-2028 (US$ Bn)
11.4.3.3. Rest of Latin America Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
11.4.3.4. Rest of Latin America Montelukast API, By Application, 2016-2028 (US$ Bn)

12. Middle East and Africa Montelukast API Market Analysis
12.1. Middle East and Africa Montelukast API Market, by Product Type, 2016-2028(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Middle East and Africa Montelukast API Market, by Dosage Form, 2016-2028(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Middle East and Africa Montelukast API Market, by Application, 2016-2028(US$ Bn)
12.3.1. Overview
12.3.2. SRC Analysis
12.4. Middle East and Africa Montelukast API Market, by Country, 2016-2028 (US$ Bn)
12.4.1. GCC Countries
12.4.1.1. GCC Countries Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.4.1.2. GCC Countries Montelukast API, By Product Type, 2016-2028 (US$ Bn)
12.4.1.3. GCC Countries Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
12.4.1.4. GCC Countries Montelukast API, By Application, 2016-2028 (US$ Bn)
12.4.2. South Africa
12.4.2.1. South Africa Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.4.2.2. South Africa Montelukast API, By Product Type, 2016-2028 (US$ Bn)
12.4.2.3. South Africa Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
12.4.2.4. South Africa Montelukast API, By Application, 2016-2028 (US$ Bn)
12.4.3. Rest of Middle East and Africa
12.4.3.1. Rest of Middle East and Africa Montelukast API Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.4.3.2. Rest of Middle East and Africa Montelukast API, By Product Type, 2016-2028 (US$ Bn)
12.4.3.3. Rest of Middle East and Africa Montelukast API, By Dosage Form, 2016-2028 (US$ Bn)
12.4.3.4. Rest of Middle East and Africa Montelukast API, By Application, 2016-2028 (US$ Bn)

13. Company Profiles
13.1. Merck & Co. Inc
13.1.1. Company Overview
13.1.2. Products/Services Portfolio
13.1.3. Geographical Presence
13.1.4. Financial Summary
13.1.4.1. Market Revenue and Net Profit (2019-2021)
13.1.4.2. Business Segment Revenue Analysis
13.1.4.3. Geographical Revenue Analysis
13.2. Cipla Limited
13.3. Morepen Laboratories
13.4. Sun Pharma
13.5. Teva Pharmaceutical Industries Ltd.
13.6. Intas Pharmaceuticals Ltd.
13.7. Apotex Inc
13.8. Sanyo Chemical Industries Ltd.
13.9. Mylan N.V.
13.10. Delmar Chemicals Inc.
13.11. Others

List of Figures

FIG. 1 Global Montelukast API Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Montelukast API Market Segmentation
FIG. 4 Global Montelukast API Market, by Product Type, 2021 (US$ Bn)
FIG. 5 Global Montelukast API Market, by Dosage Form, 2021 (US$ Bn)
FIG. 6 Global Montelukast API Market, by Application, 2021 (US$ Bn)
FIG. 7 Global Montelukast API Market, by Geography, 2021 (US$ Bn)
FIG. 8 Attractive Investment Proposition, by Product Type, 2021
FIG. 9 Attractive Investment Proposition, by Dosage Form, 2021
FIG. 10 Attractive Investment Proposition, by Application, 2021
FIG. 11 Attractive Investment Proposition, by Geography, 2021
FIG. 12 Global Market Share Analysis of Key Montelukast API Market Manufacturers, 2021
FIG. 13 Global Market Positioning of Key Montelukast API Market Manufacturers, 2021
FIG. 14 Global Montelukast API Market Value Contribution, By Product Type, 2021 & 2028 (Value %)
FIG. 15 Global Montelukast API Market, by Montelukast Sodium Amorphous, Value, 2016-2028 (US$ Bn)
FIG. 16 Global Montelukast API Market, by Montelukast Sodium Crystalline, Value, 2016-2028 (US$ Bn)
FIG. 17 Global Montelukast API Market Value Contribution, By Dosage Form, 2021 & 2028 (Value %)
FIG. 18 Global Montelukast API Market, by Tablet, Value, 2016-2028 (US$ Bn)
FIG. 19 Global Montelukast API Market, by Chewable Tablet, Value, 2016-2028 (US$ Bn)
FIG. 20 Global Montelukast API Market, by Oral Solution, Value, 2016-2028 (US$ Bn)
FIG. 21 Global Montelukast API Market Value Contribution, By Application, 2021 & 2028 (Value %)
FIG. 22 Global Montelukast API Market, by Asthma, Value, 2016-2028 (US$ Bn)
FIG. 23 Global Montelukast API Market, by Allergic Rhinitis, Value, 2016-2028 (US$ Bn)
FIG. 24 Global Montelukast API Market, by Urticaria, Value, 2016-2028 (US$ Bn)
FIG. 25 Global Montelukast API Market, by Bronchospasm, Value, 2016-2028 (US$ Bn)
FIG. 26 Global Montelukast API Market, by Others, Value, 2016-2028 (US$ Bn)
FIG. 27 U.S. Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 28 Canada Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 29 Germany Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 30 France Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 31 U.K. Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 32 Italy Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 33 Spain Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 34 Rest of Europe Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 35 China Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 36 Japan Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 37 India Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 38 South Korea Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 39 Southeast Asia Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 40 Rest of Asia Pacific Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 41 Latin America Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 42 Brazil Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 43 Mexico Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 44 Rest of Latin America Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 45 Middle East & Africa Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 46 GCC Countries Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 47 South Africa Montelukast API Market, 2016-2028 (US$ Bn)
FIG. 48 Rest of Middle East and Africa Montelukast API Market, 2016-2028 (US$ Bn)

List of Tables

TABLE 1 Market Snapshot: Global Montelukast API Market
TABLE 2 Global Montelukast API Market, by Competitive Benchmarking, 2021
TABLE 3 Global Montelukast API Market, by Geographical Presence Analysis, 2021
TABLE 4 Global Montelukast API Market, by Key Strategies Analysis, 2021
TABLE 5 Global Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 6 Global Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 7 Global Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 8 Global Montelukast API Market, by Geography, 2016-2028 (US$ Bn)
TABLE 9 North America Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 10 North America Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 11 North America Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 12 North America Montelukast API Market, by Country, 2016-2028 (US$ Bn)
TABLE 13 US Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 14 US Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 15 US Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 16 Canada Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 17 Canada Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 18 Canada Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 19 Europe Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 20 Europe Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 21 Europe Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 22 Europe Montelukast API Market, by Country, 2016-2028 (US$ Bn)
TABLE 23 Germany Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 24 Germany Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 25 Germany Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 26 France Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 27 France Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 28 France Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 29 UK Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 30 UK Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 31 UK Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 32 Italy Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 33 Italy Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 34 Italy Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 35 Spain Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 36 Spain Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 37 Spain Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 38 Rest of Europe Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 39 Rest of Europe Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 40 Rest of Europe Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 41 Asia Pacific Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 42 Asia Pacific Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 43 Asia Pacific Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 44 Asia Pacific Montelukast API Market, by Country, 2016-2028 (US$ Bn)
TABLE 45 China Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 46 China Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 47 China Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 48 Japan Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 49 Japan Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 50 Japan Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 51 India Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 52 India Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 53 India Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 54 South Korea Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 55 South Korea Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 56 South Korea Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 57 South East Asia Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 58 South East Asia Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 59 South East Asia Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 60 Rest of Asia Pacific Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 61 Rest of Asia Pacific Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 62 Rest of Asia Pacific Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 63 Latin America Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 64 Latin America Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 65 Latin America Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 66 Latin America Montelukast API Market, by Country, 2016-2028 (US$ Bn)
TABLE 67 Brazil Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 68 Brazil Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 69 Brazil Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 70 Mexico Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 71 Mexico Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 72 Mexico Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 73 Rest of Latin America Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 74 Rest of Latin America Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 75 Rest of Latin America Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 76 Middle East and Africa Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 77 Middle East and Africa Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 78 Middle East and Africa Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 79 Middle East and Africa Montelukast API Market, by Country, 2016-2028 (US$ Bn)
TABLE 80 GCC Countries Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 81 GCC Countries Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 82 GCC Countries Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 83 South Africa Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 84 South Africa Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 85 South Africa Montelukast API Market, by Application, 2016-2028 (US$ Bn)
TABLE 86 Rest of Middle East and Africa Montelukast API Market, by Product Type, 2016-2028 (US$ Bn)
TABLE 87 Rest of Middle East and Africa Montelukast API Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 88 Rest of Middle East and Africa Montelukast API Market, by Application, 2016-2028 (US$ Bn)